Physician profile
Arpan Desai
NPI 1487184685
$2,335.30
in general payments reported to CMS, 2019-2025
21 companies · $680 in 2025
The $680 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $11.23 · 2021: $130 · 2022: $234 · 2023: $490 · 2024: $791 · 2025: $680.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,960.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,960.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $395.33 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $335.65 | 2021-2025 | |
| Lilly USA, LLC | $237.76 | 2023-2025 | Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $232.38 | 2022-2025 | Farxiga, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $201.03 | 2023-2025 | Jardiance, Tradjenta |
| Exact Sciences Corporation | $174.13 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Mml US, INC. | $131.75 | 2024 | Reactiv8 |
| Esperion Therapeutics, INC. | $123.06 | 2022-2025 | Nexletol |
| Mylan Specialty L.P. | $122.67 | 2023 | Yupelri |
| Merck Sharp & Dohme LLC | $119.42 | 2020-2025 | Gardasil 9, Capvaxive, Gardasil |
| Sanofi Pasteur INC. | $71.49 | 2022-2024 | |
| Amgen INC. | $23.85 | 2025 | Repatha, Otezla |
| Phadia US INC. | $23.36 | 2024 | Immunocap |
| Glaxosmithkline, LLC. | $20.83 | 2023 | Shingrix |
| Kowa Pharmaceuticals America, INC. | $20.03 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $19.38 | 2022 | |
| Shield Therapeutics INC | $19.09 | 2025 | |
| Novartis Pharmaceuticals Corporation | $17.54 | 2022 | |
| Astellas Pharma US INC | $17.36 | 2021 | |
| Currax Pharmaceuticals LLC | $16.71 | 2025 | Contrave |
| Janssen Pharmaceuticals, INC | $12.48 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arpan Desai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.